Biotech Values

[DewDiligence]

That’s a surprisingly superficial analysis for a poster of your ilk, IMO. You fail to take into account that some of the FoB’s under development will have peak US sales that are considerably larger than Lovenox and Copaxone.

For instance, Humira will likely have annual US sales of more than $5B during the next few years, which will make it bigger than Lovenox and Copaxone combined. A sole substitutable FoB for Humira will be an enormous-selling product with essentially zero marketing costs, whether or not there are non-substitutable knockoffs on the market.